Good morning :)
Place Order
Add to Watchlist

Biocon Ltd

BIOCON

Biocon Ltd

BIOCON
Health CareBiotechnology
MidcapWith a market cap of ₹38,480 cr, stock is ranked 219
Moderate RiskStock is 2.62x as volatile as Nifty
335.004.26% (+13.70)
335.004.26% (+13.70)

Price Chart

High
—
Low
—
Returns
—
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CareBiotechnology
MidcapWith a market cap of ₹38,480 cr, stock is ranked 219
Moderate RiskStock is 2.62x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CareBiotechnology
MidcapWith a market cap of ₹38,480 cr, stock is ranked 219
Moderate RiskStock is 2.62x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
26.741.520.16%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
51.356.540.51%

Forecast & Ratings

Detailed Forecast 
57%
Analysts have suggested that investors can buy this stock

from 14 analysts

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Biocon Limited is a biopharmaceutical company engaged in the research & development and manufacture of pharmaceuticals, medicinal chemical and botanical products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 21.69%, vs industry avg of 19.21%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 84.66% to 93.82%

Higher than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of 2.46%, vs industry avg of 1.42%

Loading...

Financial YearFY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue3,716.704,064.504,350.905,854.306,529.407,410.208,396.7011,550.1015,621.2016,754.40
Raw Materialssubtract1,330.901,515.601,677.802,106.302,190.302,533.802,975.003,817.205,754.6011,781.20
Power & Fuel Costsubtract184.70156.40189.00239.80246.10270.30316.40414.80388.90
Employee Costsubtract610.10747.00931.101,165.301,458.801,741.001,880.102,181.002,664.10
Selling & Administrative Expensessubtract524.50540.10519.30846.70952.701,041.701,158.101,338.601,725.80
Operating & Other expensessubtract37.20-47.50-22.90-237.40-121.60-17.10202.201,369.301,019.40
Depreciation/Amortizationsubtract248.70277.20385.10447.80552.20715.10814.201,113.101,568.801,646.80
Interest & Other Itemssubtract29.3026.0061.5070.9064.9057.7067.60419.00974.40955.30
Taxes & Other Itemssubtract200.90237.60237.60309.60437.80327.20334.70434.40502.70931.90
EPS4.595.103.107.546.236.175.403.858.5211.99
DPS0.830.500.500.500.000.000.501.500.500.50
Payout ratio0.180.100.160.070.000.000.090.390.060.04

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

Apr 29PDF
Apr 28PDF
Mar 1PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 24PDF
Feb 17PDF
Nov 15PDF
Jul 27PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 11PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Biocon Ltd37.631.520.16%
Hester Biosciences Ltd120.457.510.22%
Panacea Biotec Ltd-1,871.552.59—
Zenotech Laboratories Ltd64.675.92—

Price Comparison

Compare BIOCON with any stock or ETF
Compare BIOCON with any stock or ETF
BIOCON
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding60.64%7.97%6.47%5.93%19.00%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep9.52%7.96%6.55%5.63%5.90%5.93%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 5 Mutual Funds holding Biocon Ltd




Funds (Top 5)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
SBI FUNDS MANAGEMENT PVT LTD#SBI MF-SBI CONTRA FUND DIRECT PL GROWTH

Growth
1.3776%1.31%-0.30%17/112 (-3)
Kotak Equity Opportunities Fund - Growth - Direct Plan

Growth
1.0679%1.64%-0.09%39/74 (-18)
SBI Balanced Advantage Fund - Direct Growth

Growth
0.8303%0.97%-0.16%81/144 (-1)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateJul 5, 2024

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 5, 2024

Cash Dividend

Ex DateEx DateJul 7, 2023

Final
Final | Div/Share: ₹1.50

Dividend/Share

₹1.50

Ex DateEx Date

Jul 7, 2023

Cash Dividend

Ex DateEx DateJun 30, 2022

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jun 30, 2022

Cash Dividend

Ex DateEx DateJul 18, 2019

Final
Final | Div/Share: ₹0.50

Dividend/Share

₹0.50

Ex DateEx Date

Jul 18, 2019

Cash Dividend

Ex DateEx DateJul 19, 2018

Final
Final | Div/Share: ₹1.00

Dividend/Share

₹1.00

Ex DateEx Date

Jul 19, 2018

News & Opinions
Spotlight
Biocon Ltd up for third consecutive session

Biocon Ltd is up for a third straight session today. The stock is quoting at Rs 327, up 1.29% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 1.04% on the day, quoting at 24230.1. The Sensex is at 79668.59, down 0.88%. Biocon Ltd has slipped around 4.58% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has slipped around 3.18% in last one month and is currently quoting at 22920.35, down 1.54% on the day. The volume in the stock stood at 15.6 lakh shares today, compared to the daily average of 28.76 lakh shares in last one month. The benchmark November futures contract for the stock is quoting at Rs 328.35, up 1.19% on the day. Biocon Ltd is up 44.15% in last one year as compared to a 24.62% jump in NIFTY and a 45.62% jump in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending September 24.Powered by Capital Market - Live

3 days agoCapital Market - Live
Spotlight
Biocon slips after recording loss of Rs 16 crore in Q2

Revenue from operations rose by 4% year-over-year (YoY) to Rs 3,590 crore during the quarter. On the segmental front, Generics business revenue was Rs 624 crore (down 8% YoY), Biosimilars revenue was Rs 2,182 crore (up 11% YoY) and Research Services revenue was Rs 891 crore (down 2% YoY). Net R&D expenses aggregated to Rs 200 crore, down 24% YoY. EBITDA declined by 20% to Rs 718 crore in Q2 FY25 from Rs 900 crore in Q2 FY24. EBITDA margin was 20% in Q2 FY25 as against 25% in Q2 FY24. Profit before tax in Q2 FY25 stood at Rs 98 crore, down by 54% from Rs 214 crore in Q2 FY24. Kiran Mazumdar-Shaw, chairperson, Biocon Group, said: 'Biocon Group's overall Q2FY25 financial and operational performance provides a foundation for improved performance as we move into the second half of the fiscal. Reported Operating Revenues of Rs 3,590 Cr reflect YoY growth of 8% on a like for like basis and core EBITDA and EBITDA margins of 28% and 20% respectively remain healthy. We had a robust performance in the Biosimilars business, up 19% on a like for like revenue basis, driven by strong market share gains in our US Oncology and Insulins franchises. Syngene has returned to sequential growth and has good visibility of a pickup in momentum in the coming quarters led by its Discovery Services and Biomanufacturing CMO business. Generics has continued to face price and demand pressures that have supressed performance, but key new formulation launches in Q3 and Q4 provide the basis of a turnaround before the year end. All three businesses are tracking towards a better performance in the second half of the year, on the back of product approvals and unfolding market opportunities. Biocon Biologics' successful refinancing of its long-term debt of US$ 1.1 billion through a combination an $800 million USD bond listed on the Singapore Stock Exchange and a new $300 million syndicated loan facility was a credible success. This was Biocon Group's debut bond issue and to be 3x oversubscribed speaks to strong investor confidence in our Biosimilars growth potential.' Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Stock Alert: L&T, Biocon, Tata Power Co, IRB Infrastructure

Securities in F&O Ban: IDFC First Bank, India Mart Intermesh, PNB, RBL Bank. Result Today: Narayana Hrudayalaya, Tata Investment Corporation, BF Investment, BF Utilities, Last Mile Enterprises, Sonalis Consumer Products, and Sudarshan Pharma Industries will declare their results today. Stocks to Watch: Biocon's consolidated net profit declined 84.3% to Rs 72 crore in Q2 FY25 from 172 crore in Q2 FY24. Revenue increased 3.6% YoY to Rs 3,590 crore during the quarter. Meanwhile, the company's drug substance facility in Bengaluru has been classified as voluntary action indicated by US Food and Drug Administration (USFDA). Larsen & Toubro reported 6.69% increase in consolidated net profit to Rs 4,113crore during the quarter as compared with Rs 3,855 crore posted in corresponding quarter last year. Revenue jumped 20.63% YoY to Rs 61,554 crore during the quarter. Tata Power Company's consolidated net profit rose 7.47% to Rs 1093 crore on 0.26% increase in revenue from operations to Rs 15,698 crore in Q2 FY25 over Q2 FY24. Meanwhile, the company filed insurance claim worth Rs 221 crore for damages incurred due to dire incident in September and received Rs 50 crore advance, final settlement to be determined on completion of assessment. Protean eGov Technologies' consolidated net profit declined 38% to Rs 28 crore on 11.8% increase in revenue from operations to Rs 220 crore in Q2 FY25 over Q2 FY24. Automotive Axles' consolidated net profit declined 20% to Rs 36 crore on 15.24% fall in consolidated revenue 15.24% to Rs 495 crore in Q2 FY25 over Q2 FY24. IRB Infrastructure's consolidated net profit jumped 4.3% to Rs 99.9 crore despite of 9.1% decline in revenue to Rs 1585.8 crore in Q2 FY25 over Q2 FY24Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Biocon reports consolidated net loss of Rs 16.00 crore in the September 2024 quarter

Net loss of Biocon reported to Rs 16.00 crore in the quarter ended September 2024 as against net profit of Rs 125.60 crore during the previous quarter ended September 2023. Sales rose 4.49% to Rs 3545.00 crore in the quarter ended September 2024 as against Rs 3392.60 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales3545.003392.60 4 OPM %19.3321.15 - PBDT492.30627.60 -22 PBT72.40238.30 -70 NP-16.00125.60 PL Powered by Capital Market - Live

1 week agoCapital Market - Live
Spotlight
Biocon Ltd spurts 1.41%, up for third straight session

Biocon Ltd rose for a third straight session today. The stock is quoting at Rs 351.4, up 1.41% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.21% on the day, quoting at 25075.15. The Sensex is at 81827.06, down 0.18%. Biocon Ltd has dropped around 10.17% in last one month. Meanwhile, Nifty Pharma index of which Biocon Ltd is a constituent, has dropped around 0.7% in last one month and is currently quoting at 23680, down 0.29% on the day. The volume in the stock stood at 8.12 lakh shares today, compared to the daily average of 43.14 lakh shares in last one month. The benchmark October futures contract for the stock is quoting at Rs 352.25, up 1.29% on the day. Biocon Ltd is up 38.24% in last one year as compared to a 27.08% gain in NIFTY and a 55.7% gain in the Nifty Pharma index.The PE of the stock is 0 based on TTM earnings ending June 24.Powered by Capital Market - Live

3 weeks agoCapital Market - Live
Corporate
Biocon announces board meeting date

Biocon will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Biocon Biologics refinances debt through USD bonds and syndicated term loan

Biocon Biologics (BBL), a subsidiary of Biocon, today announced the successful pricing of Biocon Biologics' debut USD 800 million (Rs 6676.3 crore) senior secured Notes due 2029 at a coupon of 6.67%. The Bonds will be issued by Biocon Biologics Global plc which is a wholly owned subsidiary of BBL and will be backed by a strong security package. The Bonds are expected to be rated BB by both S&P and Fitch and will be listed on the Singapore Stock Exchange. The transaction is expected to settle on October 09, 2024 subject to customary closing conditions. Additionally, Biocon Biologics has entered into a commitment agreement for a new syndicated debt facility. The proceeds of the Bonds, together with the new syndicated debt facility being raised, will be used to substantially re-finance existing debt of USD 1.1 billion (Rs 9346.8 crore) which will help improve the Company's liquidity profile, provide financial flexibility and opportunity to re-invest the cash into the business.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Biocon inks deal with Tabuk Pharma to commercialize GLP -1 products in Middle East

Tabuk Pharmaceutical Manufacturing Company is a fully-owned subsidiary of Astra Industrial Group, a leading pharmaceutical company in the Middle East and North Africa (MENA) region. Glucagon-like peptide-1 (GLP-1) are medications that help lower blood sugar levels and promote weight loss. They are physiological hormones that have multiple actions on glucose, mediated by the GLP-1 receptors released from gut enteroendocrine cells and control meal-related glycemic excursions through augmentation of insulin and inhibition of glucagon secretion. GLP-1 also inhibits gastric emptying and food intake actions, maximizing nutrient absorption while limiting weight gain. Under the terms of this agreement, Biocon will develop and manufacture the products and Tabuk Pharmaceuticals will hold the marketing authorization rights, and be responsible to register, import, and promote them in the region. The agreement also provides for a provision to expand to other glucagon-like peptide (GLP) products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage. Siddharth Mittal, chief executive officer and managing director, Biocon, said: I am pleased to expand our partnership with Tabuk Pharmaceuticals, which paves the way for our vertically integrated, complex GLP-1 formulations entry into Saudi Arabia and other countries in the region. The partnership is further validation of our concerted focus on GLPs and Peptides as future growth drivers. Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company's conosldidated net profit surged to Rs 659.7 crore in Q1 FY25 as compared with Rs 101.4 crore in Q1 FY24. Revenue from operations increased marginally year on year to Rs 3,432.9 crore in during the quarter. The scrip rose 0.35% to currently trade at Rs 373.80 on the BSE. Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Biocon signs licensing and supply agreement with Tabuk Pharmaceutical

Biocon announced the signing of a licensing and supply agreement with Tabuk Pharmaceutical Manufacturing Company (a fully-owned subsidiary of Astra Industrial Group), a leading pharmaceutical company in the Middle East and North Africa (MENA) region, to commercialize its GLP-1 products for treating diabetes and chronic weight management, in select countries of the Middle East. Under the terms of this agreement, Biocon will develop and manufacture the products and Tabuk Pharmaceuticals will hold the marketing authorization rights, and be responsible to register, import, and promote them in the region. The agreement also provides for a provision to expand to other GLP products, as well as the option of a tech transfer that will enable localized manufacturing at a later stage.Powered by Capital Market - Live

1 month agoCapital Market - Live
Spotlight
Biocon arm gets USFDA nod for chronic heart failure drug

Sacubitril and valsartan combination is used to treat chronic heart failure in adults to help reduce the risk of death and hospitalization. This medicine is also used to treat paediatric patients over the age of one year. Biocon stated that the approval further adds to its portfolio of vertically integrated, complex drug products. Biocon is an innovation led global biopharmaceuticals company, engaged in the production of therapies for chronic conditions like diabetes, cancer and autoimmune. It has developed and commercialized novel biologics, biosimilars, and complex small molecule APIs in India and several key global markets as well as Generic Formulations in the US, Europe & key emerging markets. It also has a pipeline of promising novel assets in immunotherapy under development. The company's conosldidated net profit surged to Rs 659.7 crore in Q1 FY25 as compared with Rs 101.4 crore in Q1 FY24. Revenue from operations increased marginally year on year to Rs 3,432.9 crore in during the quarter. The scrip rose 1.14% to close at Rs 359.30 on Friday, 30 August 2024. Powered by Capital Market - Live

2 months agoCapital Market - Live